Bromide

Bromide

SCHEMBL52420

[Br-].[Br-].c1ccc([P+](CCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.70
ALDH1A1 P00352 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
TSHR P16473 1/20 0.52
CYP2C19 P33261 1/20 0.52
CHRNA7 P36544 9/20 0.51
TRAP1 Q12931 3/20 0.49
SNCA P37840 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL2450121 1.00 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL7634128 1.00 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL3391859 1.00 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL4184421 1.00 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL8999525 0.97 HIF1A (0.67) HIF1AALDH1A1CYP1A2CYP2D6TSHR
SCHEMBL29466951 0.97 HIF1A (0.74) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL2446042 0.97 HIF1A (0.74) HIF1AALDH1A1CYP1A2CYP2D6TSHR
SCHEMBL29438162 0.97 HIF1A (0.74) HIF1AALDH1A1CYP1A2CYP2D6TSHR
SCHEMBL31447355 0.97 HIF1A (0.74) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Iodide SCHEMBL6060987 0.95 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150198913-A1 TRANSFER ASSIST MEMBERS XEROX CORPORATION (US) 2015-07-16 US disclosed
US-9069294-B1 Transfer assist members XEROX CORPORATION (US) 2015-06-30 US disclosed
EP-2112134-B1 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them SYNDROMEX LTD (IL) 2013-10-30 EP disclosed
US-8129552-B2 for transporting drugs or as gene transport vehicles, as solubilizers for drugs of low solubility in water, and themselves as active ingredients against diseases such as cancer or leishmaniosis; (Z)-6-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2012-03-06 US disclosed
EP-2112134-A1 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them Syndromex Ltd. (IL) 2009-10-28 EP disclosed
EP-0988274-B1 CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SYNDROMEX LTD (IL) 2009-05-20 EP disclosed
US-20080214849-A1 PHOSPHOLIPIDS WITH UNSATURATED ALKYL AND ACYL CHAINS MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSHAFTEN E.V. (DE) 2008-09-04 US disclosed
US-20060229400-A1 Powder coating matting agent comprising ester amide condensation product FLETCHER TIM 2006-10-12 US disclosed
US-20050288450-A1 Coating matting agent comprising amide condensation product FLETCHER TIM 2005-12-29 US disclosed
EP-1509561-A1 POWDER COATING MATTING AGENT COMPRISING ESTER AMIDE CONDENSATION PRODUCT Grace GmbH & Co. KG (DE) 2005-03-02 EP disclosed
US-20040132818-A1 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them SYNDROMEX LTD. (IL) 2004-07-08 US disclosed
WO-2003102048-A1 POWDER COATING MATTING AGENT COMPRISING ESTER AMIDE CONDENSATION PRODUCT GRACE GMBH & CO. KG (DE) 2003-12-11 WO disclosed
US-20020049345-A1 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them SYNDROMEX LTD. (IL) 2002-04-25 US disclosed
EP-0780452-B1 Aqueous paint TOYO SEIKAN KAISHA LTD (JP) 2002-03-06 EP disclosed
US-6284903-B1 TREATING HYPERLIPIDEMIA, OBESITY AND IMPAIRED GLUCOSE TOLERANCE/NONINSULIN DEPENDENT DIABETES MELLITUS WITHOUT ADVERSELY AFFECTING ENERGY METABOLISM YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2001-09-04 US disclosed
US-5763507-A EPOXY ACRYLATE RESIN TOYO SEIKAN KAISHA, LTD. (JP) 1998-06-09 US disclosed
EP-0780452-A2 Aqueous paint TOYO SEIKAN KAISHA LIMITED (JP) 1997-06-25 EP disclosed
US-5310854-A Solvent, coatings for beverage cans THE DOW CHEMICAL COMPANY (US) 1994-05-10 US disclosed
US-4933420-A Epoxy resins containing phosphonium catalysts THE DOW CHEMICAL COMPANY (US) 1990-06-12 US disclosed
EP-0360195-A2 Epoxy resins containing phosphonium catalysts THE DOW CHEMICAL COMPANY (US) 1990-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132818-A1 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them CYP2F1, QPCT, CBR3 HIF1A 1562/4885ALDH1A1 209/4885CYP1A2 300/4885
US-20080214849-A1 PHOSPHOLIPIDS WITH UNSATURATED ALKYL AND ACYL CHAINS PHOSPHO1, PLTP, SGMS1 HIF1A 4557/4885ALDH1A1 4394/4885CYP1A2 3227/4885
US-20020049345-A1 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them CYP2F1, QPCT, CYP2D6 HIF1A 1474/4885ALDH1A1 206/4885CYP1A2 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.